STAA STAAR Surgical Corp: רווח למניה ב-12 החודשים האחרונים

STAAR Surgical Company (STAA) is undergoing a recovery phase in demand for elective vision treatment, as confirmed by the historical YoY TTM EPS delta. Unique EVO implants provide significant pricing power, while outsourcing production and logistics to external partners optimizes costs. Consequently, 100.60 becomes the new value of the indicator, demonstrating earnings per share dynamics relative to the sector.
פילוחי מדדים פיננסיים ומדדי שוק עבור STAAR Surgical Co (STAA)

Investors are assessing the potential of STAAR Surgical Company (STAA) through the business's ability to scale profits, where the calculated EPS TTM growth measures the percentage change in net income per share over the last twelve months relative to the previous year. By analyzing the annual growth rate of TTM net income per share, one can determine the extent to which the implementation of robotic lines and AI lens control actually optimizes costs and increases final shareholder returns.